Research programme: beta-amyloid inhibitors - Scios/Eli Lilly and Company
Latest Information Update: 01 Aug 2002
Price :
$50 *
At a glance
- Originator Eli Lilly and Company; Scios
- Class
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 27 Jun 2000 Preclinical development for Alzheimer's disease in USA (Unknown route)